O
Ole Schmitz
Researcher at Aarhus University Hospital
Publications - 295
Citations - 20760
Ole Schmitz is an academic researcher from Aarhus University Hospital. The author has contributed to research in topics: Insulin & Insulin resistance. The author has an hindex of 68, co-authored 284 publications receiving 19914 citations. Previous affiliations of Ole Schmitz include Aarhus University & Steno Diabetes Center.
Papers
More filters
Journal ArticleDOI
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial.
John A. Dormandy,Bernard Charbonnel,David Eckland,Erland Erdmann,Massimo Massi-Benedetti,Ian K. Moules,Allan M. Skene,Meng H. Tan,P. J. Lefebvre,Gordon D Murray,Eberhard Standl,Robert G. Wilcox,Lars Wilhelmsen,John Betteridge,Kåre I. Birkeland,Alain Golay,Robert J. Heine,László Korányi,Markku Laakso,Marián Mokáň,Antanas Norkus,Valdis Pirags,Toomas Podar,André Scheen,Werner A. Scherbaum,Guntram Schernthaner,Ole Schmitz,Jan Škrha,Ulf Smith,Jan Tatoň +29 more
TL;DR: Overall safety and tolerability was good with no change in the safety profile of pioglitazone identified; mortality rates from heart failure did not differ between groups.
Journal ArticleDOI
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
David Russell-Jones,Allan Vaag,Ole Schmitz,B. K. Sethi,N. lalic,S. Antic,Milan Zdravkovic,G. M. Ravn,Rafael Simó +8 more
TL;DR: Liraglutide added to metformin and sulfonylurea produced significant improvement in glycaemic control and bodyweight compared with placebo and insulin glargine.
Journal ArticleDOI
Effect of valsartan on the incidence of diabetes and cardiovascular events.
John J.V. McMurray,Rury R. Holman,Steven M. Haffner,M A Bethel,Bjoern Holzhauer,Tsushung Hua,Yuri N. Belenkov,Mitradev Boolell,John B. Buse,Brendan M. Buckley,Antonio Roberto Chacra,Fu-Tien Chiang,Bernard Charbonnel,Chun Chung Chow,Melanie J. Davies,Prakash Deedwania,Peter Diem,Daniel Einhorn,Vivian Fonseca,Gregory R. Fulcher,Zbigniew Gaciong,Sonia Gaztambide,Thomas D. Giles,Edward S. Horton,Hasan Ilkova,Trond Jenssen,Steven E. Kahn,Henry Krum,Markku Laakso,Lawrence A. Leiter,Naomi S. Levitt,Viacheslav Mareev,Felipe Martinez,Chantal Masson,Theodore Mazzone,Eduardo Meaney,Richard W. Nesto,Chang-yu Pan,R. Prager,Sotirios A. Raptis,Guy E.H.M. Rutten,Herbert Sandstroem,Frank Schaper,André Scheen,Ole Schmitz,Isaac Sinay,Vladimír Soška,Steen Stender,Gyula Tamás,Gianni Tognoni,Jaakko Tuomilehto,Alberto S. Villamil,Juraj Vozar,Robert M. Califf +53 more
TL;DR: Among patients with impaired glucose tolerance and cardiovascular disease or risk factors, the use of valsartan for 5 years, along with lifestyle modification, led to a relative reduction of 14% in the incidence of diabetes but did not reduce the rate of cardiovascular events.
Journal ArticleDOI
Contraction stimulates translocation of glucose transporter GLUT4 in skeletal muscle through a mechanism distinct from that of insulin
TL;DR: Contraction-mediated translocation of the GLUT4 transporters to the cell surface was closely correlated with the glucose transport activity and could account fully for the increment in glucose uptake after contraction.
Journal ArticleDOI
Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes
Tina Vilsbøll,Milan Zdravkovic,Tu Le-Thi,Thure Krarup,Ole Schmitz,J.-P. Courreges,Robert Verhoeven,Ingrid Bugánová,Sten Madsbad +8 more
TL;DR: In this paper, the authors evaluated the efficacy and safety after 14 weeks' treatment with liraglutide in patients with type 2 diabetes and found that the placebo group accounted for almost one-half of the patient withdrawals, primarily due to ineffective therapy.